CD36 and neoplasm: Our laboratory has previously shown that isogenic patient-derived xenograft (PDX) tumors, which were established from isolating tumor cells expressing high levels of CD36 (CD36high), have a higher propensity to grow subcutaneous tumors in vivo [15].